Ask Mallard
Study design

3+3 dose-escalation design

4 min read

The 3+3 design uses fixed rules for small cohorts to guide escalation; it does not fit a dose-toxicity model.

NHMRC EVIDENCE LEVEL · 2009Outside the NHMRC hierarchy
Why this level?not one of the five research areas this hierarchy covers. NHMRC 2009 source

Dose selection is a feasibility and safety question, not one of the five research areas this hierarchy covers. It does not establish comparative treatment benefit.

Fit

When to use it, and when not to

Use it when

  • You need to select a dose for later study under a prespecified safety plan.
  • The toxicity outcome and its observation window can guide the next allocation.

Not when

Before you start

What you need

Decide these first
  1. Toxicity definition and targetDefine a dose-limiting toxicity and the full assessment window before recruitment.
  2. Dose levels and safety limitsFix the starting dose, allowed moves, stopping rules and independent safety oversight.
  3. Simulated trial scenariosVary toxicity curves, accrual and delayed harm. Check selection accuracy and exposure to unsafe doses.
It rests on these
  1. Pending toxicity is not absence of toxicity.How to check: Wait for the required window or use a validated extension designed for partial follow-up.
  2. The dose ordering and safety target fit the treatment.How to check: Toxicity-focused dose selection may not identify the best benefit-risk balance or biological dose.

Plain language

How it works

Treat three patients at a dose and complete the toxicity window. A common rule escalates if none has a dose-limiting toxicity. One toxicity expands the cohort to six. At least two toxicities stop escalation at that dose. After expansion, one of six can permit escalation; at least two of six stop it. The protocol must specify the final dose choice and safety stopping rules.

What the rule cannot establish

The rule is simple but its dose-selection behavior depends on the toxicity curve and starting dose. It does not directly choose an arbitrary target toxicity probability. Simulate the complete protocol and assess both unsafe and ineffective dosing.

The structure of the approach
Prespecified safety rules govern each level decision. Pending follow-up is not absence of toxicity. The complete design needs simulation under plausible scenarios. Selecting or expanding a level does not confirm efficacy.Prespecified safety rules govern each level decisionDefine target and safetyrulesObserve outcomes andpending follow-upApply the chosen designand safety constraintsEscalate only whenpermittedRetain or reduce levelStop when requiredPending follow-up is not absence of toxicity. The complete design needs simulation under plausiblescenarios. Selecting or expanding a level does not confirm efficacy.
Conceptual diagram. It shows the structure of the idea, not data from any study.

Worked example

A worked example

Invented for illustration
Setting
An early-phase trial follows a prespecified toxicity window.
Question
What do the observed counts imply under the stated design?
Approach
Three patients complete the window at one dose; one has a dose-limiting toxicity. The stated 3+3 rule expands that dose.
Result
One of three patients has a toxicity, about 33 in 100. The cohort expands from 3 to 6 patients.
What it means
The next decision depends on all six outcomes. This observed share is not a precise toxicity risk.

In practice

Recent studies PubMed search · not vetted

Searching PubMed…

Watch out

Common mistakes

The one to remember

A familiar cohort rule is not a guarantee of safety or correct dose selection. State the exact variant, final selection rule and stopping policy.

  • Equating dose selection with proof of efficacy.Instead: Selection is uncertain. Confirm benefit in a suitable later trial.
  • Changing allocation rules after a worrying result.Instead: Apply the prespecified safety and stopping rules with the safety team.

Inside Mallard

How Mallard uses this

Plans do not link to this design yet. Mallard has no sample-size form for the 3+3 dose-escalation design. A plan sized by simulation gets no headline sample size; Mallard does not run that simulation.

No Mallard code example points to this page.
Atlas node design.three_plus_three, the id a plan cue records.

How to report it

Use CONSORT-DEFINE to report the dose-selection goal, toxicity window, allocation, safety and stopping rules, deviations and participant flow. Separate observed toxicity from model estimates. State the final dose recommendation and its uncertainty. A reporting guideline is not a design manual: use it to make the study transparent, not as a substitute for careful design. Check the target journal's own requirements as well, which this page cannot know.

Related Learn pages

Related designs and methods

Evidence

Sources & further reading

  1. Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents (opens in a new tab) · PLoS One · doi 10.1371/journal.pone.0051039
  2. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials (opens in a new tab) · Clin Cancer Res · doi 10.1158/1078-0432.CCR-16-0592
  3. Dose escalation methods in phase I cancer clinical trials (opens in a new tab) · J Natl Cancer Inst · doi 10.1093/jnci/djp079
  4. Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance (opens in a new tab) · BMJ · doi 10.1136/bmj-2023-076387
Prepared with AI assistance. PubMed records checked on 2026-11-07 UTC for title, authors, year and available DOI. Record verified, confirm it supports this use. No independent professional or methodological approval is claimed.
Last source review: 2026-11-07
AI-generated educational content
Mallard uses reputable methodological and reporting sources, but this material may contain errors or omit important context. Verify important methodological decisions with the cited sources and, when appropriate, a qualified research methodologist or statistician.